SS Innovations Launches Sri Lanka's First Robotic Cardiac Surgery Program with SSi Mantra 3.0

SS Innovations International Inc. (NASDAQ: SSII) has taken a significant step in expanding the global reach of robotic cardiac surgery by supporting the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a milestone for both the company and the Sri Lankan healthcare sector.

The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration underscores the company's commitment to bringing advanced surgical technology to new markets and training local surgeons in robotic techniques.

According to a recent company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system. This early success suggests that robotic cardiac surgery can be effectively integrated into healthcare systems outside of major established markets.

The launch comes as SS Innovations reports strong operational momentum. At the end of the second quarter, the company had 224 cumulative SSi Mantra installations across 12 countries. Revenue for the second quarter reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures point to rising utilization of the company's installed base, which is critical for recurring revenue and long-term growth.

The next major corporate milestone for SS Innovations is regulatory expansion. The company is actively pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open access to two of the largest healthcare markets in the world, significantly expanding the company's addressable market and competitive positioning.

For investors, the Sri Lanka program demonstrates tangible progress in commercializing the SSi Mantra platform and validates its clinical utility in cardiac surgery, a complex and high-value specialty. The combination of growing installations, increasing procedure volumes, and impending regulatory decisions positions SS Innovations for potential acceleration in revenue and market share.

The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For more information about TechMediaWire, please visit https://www.TechMediaWire.com. Full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.